Abstract
Biomarkers in the clinical oncology field can have tremendous therapeutic impact especially if the marker is detected before clinical symptoms. This impact can be extended to the evaluation of clinical oncology treatments allowing evaluation of potential compounds to determine their efficacy in the disease treatment. The discovery of clinical biomarkers can consume time, resources and costs. Therefore, it is important that the most effective strategies are employed to discover these biomarkers. These strategies may include the integration of available genomic, proteomic and histopathological technologies, which could reduce the costs and aid in the validation of the biomarker. Certainly the type of biomarker needed to address a particularly defined problem will drive the type of technology. However, a single biomarker to diagnose a specific cancer can be as elusive as relying on a single technology. This review examines some of the technologies used to discover biomarkers and presents the use of combinatorial technical synergies to discover and validate potential clinical oncology biomarkers.
Keywords: biomarker, oncology, integration, functional informatics, proteomics, genomics, histology
Current Topics in Medicinal Chemistry
Title: Synergistic Approaches to Clinical Oncology Biomarker Discovery
Volume: 5 Issue: 11
Author(s): Stanley M. Belkowski, Deborah Polkovitch and Michael R. D'Andrea
Affiliation:
Keywords: biomarker, oncology, integration, functional informatics, proteomics, genomics, histology
Abstract: Biomarkers in the clinical oncology field can have tremendous therapeutic impact especially if the marker is detected before clinical symptoms. This impact can be extended to the evaluation of clinical oncology treatments allowing evaluation of potential compounds to determine their efficacy in the disease treatment. The discovery of clinical biomarkers can consume time, resources and costs. Therefore, it is important that the most effective strategies are employed to discover these biomarkers. These strategies may include the integration of available genomic, proteomic and histopathological technologies, which could reduce the costs and aid in the validation of the biomarker. Certainly the type of biomarker needed to address a particularly defined problem will drive the type of technology. However, a single biomarker to diagnose a specific cancer can be as elusive as relying on a single technology. This review examines some of the technologies used to discover biomarkers and presents the use of combinatorial technical synergies to discover and validate potential clinical oncology biomarkers.
Export Options
About this article
Cite this article as:
Belkowski M. Stanley, Polkovitch Deborah and D'Andrea R. Michael, Synergistic Approaches to Clinical Oncology Biomarker Discovery, Current Topics in Medicinal Chemistry 2005; 5 (11) . https://dx.doi.org/10.2174/156802605774297074
DOI https://dx.doi.org/10.2174/156802605774297074 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Involvement of Metallothioneins in Mitochondrial Function and Disease
Current Protein & Peptide Science Natural Sesquiterpenoids as Cytotoxic Anticancer Agents
Mini-Reviews in Medicinal Chemistry Nasal Polyposis: An Overview of Differential Diagnosis and Treatment
Recent Patents on Inflammation & Allergy Drug Discovery Safety of the Thrombopoiesis-Stimulating Agents for the Treatment of Immune Thrombocytopenia
Current Drug Safety Lentiviral Vectors: A Versatile Tool to Fight Cancer
Current Molecular Medicine Role of Metallothionein in Inflammatory Lung Diseases
Current Respiratory Medicine Reviews Issues in the Psychiatric Screening of Cancer Patients
Current Psychiatry Reviews Does Metformin Satisfy as an Option for Host-Directed Therapy in COVID-19?
Anti-Infective Agents Glucose Oncometabolism of Esophageal Cancer
Anti-Cancer Agents in Medicinal Chemistry Pharmacokinetic and Pharmacogenetic Markers of Irinotecan Toxicity
Current Medicinal Chemistry Histone Modifications as Molecular Targets in Nasopharyngeal Cancer
Current Medicinal Chemistry Bcl-2 Family Proteins as Therapeutic Targets
Current Pharmaceutical Design Liposomes as Nanovaccine Delivery Systems
Current Topics in Medicinal Chemistry Nanotechology-Based Strategies to Enhance the Efficacy of Photodynamic Therapy for Cancers
Current Drug Metabolism Physcion and Physcion 8-O-β-D-glucopyranoside: Natural Anthraquinones with Potential Anticancer Activities
Current Drug Targets The Glycogen Synthase Kinase-3 in the Regulation of Ion Channels and Cellular Carriers
Current Medicinal Chemistry LncRNA HOTAIR as Prognostic Circulating Marker and Potential Therapeutic Target in Patients with Tumor Diseases
Current Drug Targets Targeting ADAM17 Sheddase Activity in Cancer
Current Drug Targets Key miRNAs in Modulating Aging and Longevity: A Focus on Signaling Pathways and Cellular Targets
Current Molecular Pharmacology Exposure and Genotoxicity Assessment Methodologies - The Case of Formaldehyde Occupational Exposure
Current Analytical Chemistry